Genetically Modified T cells Targeting Interleukin-11 Receptor α-Chain Kill Human Osteosarcoma Cells and Induce the Regression of Established Osteosarcoma Lung Metastases
Open accessThe DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.
Abstract
The treatment of osteosarcoma pulmonary metastases remains a challenge. T cells genetically modified to express a chimeric antigen receptor (CAR), which recognizes a tumor-associated antigen, have shown activity against hematopoietic malignancies in clinical trials, but this requires the identification of a specific receptor on the tumor cell. In the current study, we found that interleukin (IL)-11Rα was selectively expressed on 14 of 16 osteosarcoma patients' lung metastases and four different human osteosarcoma cell lines, indicating that IL-11Rα may be a novel target for CAR-specific T-cell therapy. IL-11Rα expression was absent or low in normal organ tissues, with the exception of the gastrointestinal tract. IL-11Rα-CAR–specific T cells were obtained by non-viral gene transfer of Sleeping Beauty DNA plasmids and selectively expanded ex vivo using artificial antigen-presenting cells derived from IL-11Rα + K562 cells genetically modified to coexpress T-cell costimulatory molecules. IL-11Rα-CAR+ T cells killed all four osteosarcoma cell lines in vitro; cytotoxicity correlated with the level of IL-11Rα expression on the tumor cells. Intravenous injection of IL-11Rα-CAR+ T cells into mice resulted in the regression of osteosarcoma pulmonary metastases with no organ toxicity. Together, the data suggest that IL-11Rα-CAR T cells may represent a new therapy for patients with osteosarcoma pulmonary metastases. Cancer Res; 72(1); 271–81. ©2011 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Zhang et al. conducted the third-generation CAR-T cells targeting B7-H3 and proved the killing effects for tumor cells in vitro and in vivo using the patientderived xenografts (PDXs) model of osteosarcoma [116–125].”
From Advances on immunotherapy for osteosarcoma (2024) · cites this paper as [123]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“IL-11Rα-CAR-T cells not only killed the osteosarcoma cell lines expressing IL-11Rα, but also results in the regression of osteosarcoma lung metastases.”
From Advances on immunotherapy for osteosarcoma (2024) · cites this paper as [123]
The cited source says what the claim attributes to it.
In the citing paper
“the cytotoxicity of IL-11Rα-CAR-T cells correlated with level of IL-11Ra expression on osteosarcoma cells [123].”
From Advances on immunotherapy for osteosarcoma (2024) · cites this paper as [123]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interleukin-6 family of cytokines and gp130
Kishimoto, T., Akira, S., Narazaki, M., & Taga, T. (1995) · Blood · doi:10.1182/blood.v86.4.1243.bloodjournal8641243 · Cited by 1,272 · cited 2×
“IL-11 is a member of a family of pleiotropic cytokines that include IL-6, leukemia-inhibitory factor, oncostatin M, and ciliary neurotrophic factor (12, 13).”
Link, M. P., Goorin, A. M., Miser, A. W., Green, A. A., Pratt, C. B., Belasco, J. B., Pritchard, J., Malpas, J. S., Baker, A. R., Kirkpatrick, J. A., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198606193142502 · Cited by 1,204 · cited 1×
“3 Introduction Despite multiple changes in the adjuvant chemotherapy regimens used to treat patients with osteosarcoma (OS), both the 2-year metastasis-free survival and the overall survival rates have remained stagnant at 65-70% for the past 20 years [1-6].”
Gene splicing and mutagenesis by PCR-driven overlap extension
Heckman, K. L., & Pease, L. R. (2007) · Nature Protocols · doi:10.1038/nprot.2007.132 · Cited by 1,144
Meyers, P. A., Schwartz, C. L., Krailo, M. D., Healey, J. H., Bernstein, M. L., Betcher, D., Ferguson, W. S., Gebhardt, M. C., Goorin, A. M., Harris, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.14.0095 · Cited by 752 · cited 1×
“in a clinically significant improvement in the overall survival rate 6 to 12 years after initial diagnosis (8, 9).”
Self-citationChemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience.
Meyers, P. A., Heller, G., Healey, J., Huvos, A., Lane, J., Marcove, R., Applewhite, A., Vlamis, V, & Rosen, G. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.1.5 · Cited by 678
Kempf-Bielack, B., Bielack, S. S., Jürgens, H., Branscheid, D., Berdel, W. E., Exner, G. U., Göbel, U., Helmke, K., Jundt, G., Kabisch, H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.063 · Cited by 643 · cited 1×
“Salvage chemotherapy has failed to improve survival (27).”
Steps toward mapping the human vasculature by phage display
Arap, W., Kolonin, M. G., Trepel, M., Lahdenranta, J., Cardó-Vila, M., Giordano, R. J., Mintz, P. J., Ardelt, P. U., Yao, V. J., Vidal, C. I., et al. (2002) · Nature Medicine · doi:10.1038/nm0202-121 · Cited by 607
Adoptive T cell therapy for cancer in the clinic
June, C. H. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32446 · Cited by 553 · cited 1×
“T-cell infusions have also been shown to recruit other cytotoxic effector cells which again may have therapeutic benefit (39, 40).”
Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial.
Eilber, F., Giuliano, A., Eckardt, J., Patterson, K., Moseley, S., & Goodnight, J. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.1.21 · Cited by 529 · cited 1×
“3 Introduction Despite multiple changes in the adjuvant chemotherapy regimens used to treat patients with osteosarcoma (OS), both the 2-year metastasis-free survival and the overall survival rates have remained stagnant at 65-70% for the past 20 years [1-6].”
Kowolik, C. M., Topp, M. S., Gonzalez, S., Pfeiffer, T., Olivares, S., Gonzalez, N., Smith, D. D., Forman, S. J., Jensen, M. C., & Cooper, L. J. N. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0160 · Cited by 487 · cited 1×
“A second-generation CAR using dual endodomains CD28 and CD3-z improves T-cell activation (29).”
Self-citation
Cited by
Ahmed, N., Brawley, V. S., Hegde, M., Robertson, C., Ghazi, A., Gerken, C., Liu, E., Dakhova, O., Ashoori, A., Corder, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.0225 · Cited by 1,004
Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs
Chen, C., Xie, L., Ren, T., Huang, Y., Xu, J., & Guo, W. (2021) · Cancer Letters · doi:10.1016/j.canlet.2020.12.024 · Cited by 569
Design and development of therapies using chimeric antigen receptor‐expressing T cells
Dotti, G., Gottschalk, S., Savoldo, B., & Brenner, M. K. (2014) · Immunological Reviews · doi:10.1111/imr.12131 · Cited by 508
“B7H3 (60) Sarcoma, glioma scFv, protein CAIX (61, 62) Kidney scFv, protein Published CD44 v6/v7 (63, 64) Cervical scFv, protein CD171 (65) Neuroblastoma scFv, protein Published CEA (66) Colon scFv, protein Ongoing EGFRvIII (67, 68) Glioma scFv, protein Ongoing EGP2 (69, 70) Carcinomas scFv, protein EGP40 (71) Colon sc…”
Gene-engineered T cells for cancer therapy
Kershaw, M. H., Westwood, J. A., & Darcy, P. K. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3565 · Cited by 505
Advances on immunotherapy for osteosarcoma
Yu, S., & Yao, X. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02105-9 · Cited by 270
“Besides, the cytotoxicity of IL-11Rα-CAR-T cells correlated with level of IL-11Ra expression on osteosarcoma cells [123].”
Background
Metadata
- Authors
- Huang, G., Yu, L., Cooper, L. J. N., Hollomon, M., Huls, H., & Kleinerman, E. S.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Kleinerman, Eugenie S.
- Venue
- Cancer Research
- Published
- 2012-01-01
- Volume
- 72
- Issue
- 1
- Pages
- 271-281
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- PMC
- PMC3833671
- OpenAlex
- W2140821500
- Cited by
- 127
- References
- 44
- Citations by year
- 2026: 7 · 2025: 10 · 2024: 4 · 2023: 11 · 2022: 13 · 2021: 10 · 2020: 8 · 2019: 4 · 2018: 11 · 2017: 13 · 2016: 10 · 2015: 10 · 2014: 7 · 2013: 8 · 2012: 1
- FWCI
- 2.52
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (CA-16672, R01CA141303, R01 CA 42992, R01CA042992, P30CA016672)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Keywords
- osteosarcoma, lung metastasis, chimeric antigen receptor T cells, adoptive T cell therapy, tumor-associated antigens, Sleeping Beauty transposon, artificial antigen-presenting cells, K562 cells, tumor regression, selective tumor targeting
- MeSH terms
- Animals, Bone Neoplasms, Flow Cytometry, Humans, Immunohistochemistry, Lung Neoplasms, Mice, Nude, Neoplasm Metastasis, Plasmids, Osteosarcoma, T-Lymphocytes, Electroporation, Cell Line, Tumor, Mice, Interleukin-11 Receptor alpha Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Genetically Modified T cells Targeting Interleukin-11 Receptor α-Chain Kill Human Osteosarcoma Cells and Induce the Regression of Established Osteosarcoma Lung Metastases. https://app.cochat.ai/papers/10.1158/0008-5472.can-11-2778
- The paper
- Huang, G., Yu, L., Cooper, L. J. N., Hollomon, M., Huls, H., & Kleinerman, E. S. (2012). Genetically Modified T cells Targeting Interleukin-11 Receptor α-Chain Kill Human Osteosarcoma Cells and Induce the Regression of Established Osteosarcoma Lung Metastases. Cancer Research. https://doi.org/10.1158/0008-5472.can-11-2778
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.